The U.S. Court of Appeals for the Federal Circuit on Monday upheld a Patent Trial and Appeal Board decision awarding CRISPR-Cas9 patents on human and animal gene editing to the Broad Institute of MIT and Harvard.
The ruling settles an initial clash over foundational patents to technology that can be used to add or delete DNA from cells in order to fight diseases, reverse genetic mutations or to improve crop resistance to pests and drought.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]